11. Allergic and immunologic diseases of the skin

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 2 SUPPL. 2, 2003, Pages

  Blauvelt, Andrew ^a   Hwang, Sam T ^a   Udey, Mark C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allergic contact dermatitis; Atopic dermatitis; Autoantibodies; Chemokines; Immunopathogenesis; Immunotherapeutics; Pemphigus; Psoriasis; Urticaria

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; AZATHIOPRINE; CALCIPOTRIOL; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DOXEPIN; EMOLLIENT AGENT; ETRETIN; FEXOFENADINE; FLUOCINONIDE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 2 DERIVATIVE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PSORALEN; RETINOID DERIVATIVE; SOAP; TACROLIMUS; TAZOROTENE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATOPIC DERMATITIS; CLINICAL FEATURE; CONTACT DERMATITIS; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG PROTEIN BINDING; GENETICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NONHUMAN; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHOTOTHERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; T LYMPHOCYTE; URTICARIA;

EID: 0037326199     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.78     Document Type: Review

References (64)

1. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;133:450-6.
2. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974;109:207-11.
3. Elder JT, Nair RP, Henseler T, Jenisch S, Stuart P, Chia N, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 2001;137:1447-54.
4. Piepkorn M, Pittelkow MR, Cook PW. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998;111:715-21.
5. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
6. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-5.
7. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
8. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
9. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94.
10. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47.
11. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6.
12. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodsworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
13. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
14. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000;43:448-58.
15. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000;43:595-604.
16. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
17. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
18. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
19. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, et al. Clinical and immunologic assessment of patients with psoriasis in a randomized double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 2002;138:1341-6.
20. Trepicchio WL, Ozawa M, Walters IB, Kikucki T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37.
21. Krueger J, Glottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T- cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000;11:333.
22. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
23. Rietschel RL, Fowler JF, editors. Fisher's Contact Dermatitis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 862.
24. Girolomoni G, Sebastiani S, Albanesi C, Cavani A. T-cell subpopulations in the development of atopic and contact allergy. Curr Opin Immunol 2002;13:733-7.
25. Gorbachev AV, Fairchild RL. Induction and regulation of T-cell priming for contact sensitivity. Crit Rev Immunol 2001;21:415-72.
26. Marks JG, Belsito DV, DeLeo VA, Fowler JF, Fransway AF, Maibach HI. North American Contact Dermatitis Group patch-test results. Arch Dermatol 2000;136:272-3.
27. English J. Current concepts in contact dermatitis. Br J Dermatol 2001;145:527-9.
28. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44(1 Suppl):S1-S12.
29. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804.
30. One PY, Hamid QA, Travers JB, Strickland I, Al Kerithy M, Boguniewicz M, et al. Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis. J Immunol 2002;168:505-10.
31. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 1999;50:425-40.
32. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG, et al. A Th2 chemokine, TARC. produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000;115:640-6.
33. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-41.
34. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000;164:1612-6.
35. Eigenmann PA, Calza AM. Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis. Pediatr Allergy Immunol 2000;11:95-100.
36. Wananukul S, Huiprasert P, Pongprasit P. Eczematous skin reaction from patch testing with aeroallergens in atopic children with and without atopic dermatitis. Pediatr Dermatol 1993;10:209-13.
37. Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001;56:1034-41.
38. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001;108:269-74.
39. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001;44(1 Suppl):S13-6.
40. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44(1 Suppl):S47-57.
41. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:2012-6.
42. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002;27:3-7.
43. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.
44. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002;46:645-57.
45. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria - a clinical, immunological and histological evaluation. Br J Dermatol 1986;114:583-90.
46. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-604.
47. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, et al. Serum IgG autoantibodies directed against the alpha chain of Fe epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995;96:2606-12.
48. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101:243-51.
49. Diaz L, Giudice GJ. End of the century overview of blisters. Arch Dermatol 2000;136:106-12.
50. Green KJ, Gaudry CA. Are desmosomes more than tethers for intermediate filaments? Nat Rev Mol Cell Biol 2000;1:208-16.
51. Stanley JR. Pemphigus. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB. Dermatology in General Medicine, 5th ed. New York: McGraw-Hill; 1999. p. 654-66.
52. Anhalt GJ, Diaz, LA. Research advances in pemphigus. JAMA 2001;285:652-4.
53. Nguyen VT, Ndole A, Shultz LD, Pittelkow MR, Grando SA, Antibodies against keratinocyte antigens other than desmogleins 1 and 2 can induce pemphigus valgaris-like lesions. J Clin Invest 2000;106:1467-79.
54. Udey MC, Stanley JR. Pemphigus-diseases of antidesmosomal autoimmunity. JAMA 1999;282:572-6.
55. Koch PJ, Mahoney MG, Ishikawa H, Pulkkinen L, Uitto J, Murphy GF, Whitaker-Menezes D, Stanley JR. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997;137:1091-102.
56. Tsundo K, Ota T, Ohyama M, Nagai T, Nishikawa T, Amagai M, et al. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol 2002;32:627-33.
57. Amagai M, Komai A, Hashimoto T, Shirakata Y, Hashimoto K, Yamada T, Usefulness of enzyme-linked immunoadsorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis. Br J Dermatol 1999;140:351-7.
58. Amagai M, Matsuyoshi N, Wang ZH, Andl C. Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein I. Nat Med 2000;6:1275-7.
59. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein I. J Invest Dermatol 2002;118:845-50.
60. Eaton DP, Diaz LA, Hans-Filho G, Santos VD, Aoki V, Friedman H. Comparison of black fly species (Diptera: Simuliidae) on an Amerindian reservation with a high prevalence of fogo salvagem to neighboring disease-free sites in the State of Mato Grosso do Sol, Brazil. The cooperative group on logo salvagem research. J Med Entomol 1998;35:120-31.
61. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997;12:77-96.
62. Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998;111:308-13.
63. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in the sera of patients with paraneoplastic pemphigus and cause acantholysis in neonatal mice. J Clin Invest 1998;102:775-82.
64. Bowen GM, Peters NT, Fivenson DP, Su LD, Nousari HC, Anhalt GJ, Cooper KD. Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading? Arch Dermatol 2000;136:652-6.